Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825023 | Clinical Therapeutics | 2015 | 11 Pages |
Abstract
Treatment with liraglutide in a real-world setting is associated with low therapy failure, good glycemic response, weight loss, and improvement in systolic blood pressure and lipid profile. The HbA1c drop did not differ among baseline BMI classes, indicating that efficacy is maintained in patients with lower BMI. The probability of reaching HbA1c â¤7% was significantly higher in patients previously treated with metformin alone and without any previous insulin. This could reinforce the hypothesis that better results with liraglutide could be achieved in patients after early metformin failure.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Annunziata MD, Vera MD, Michela MD, Michela Dal MD, Paola MD, Giuseppe MD, Federica MD, Virgilio Da MD, Michele MD, Alberto MD, Maria MD, Alessandro MD, Sara MD, Loris MD, Mario MD, Narciso MD, Marco MD, Elisabetta MD, Natalino MD,